Change in Apo B100/A1 Ratio in Children With Epilepsy on Monotherapy With Sodium Valproate, Oxcarbazepine or Levetiracetam.

A prospective longitudinal study was conducted to assess the Apo B100/A1 ratio as a marker of cardiovascular risk in children with epilepsy aged 5-14 years on long-term anti-seizure medication monotherapy with either sodium valproate, oxcarbazepine, or levetiracetam. Apo B100/A1 ratio showed an increase after six months of monotherapy with oxcarbazepine (P=0.05).